Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
ALX Oncology Inc.
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Travera Inc
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Turning Point Therapeutics, Inc.
Eastern Cooperative Oncology Group
Kaiser Permanente
Duke University
Washington University School of Medicine
Arvinas Inc.
University of Colorado, Denver
City of Hope Medical Center
University of Nebraska
Eli Lilly and Company
Novartis
Var2 Pharmaceuticals
Radboud University Medical Center
Takeda
University Health Network, Toronto
Tempus AI
Massive Bio, Inc.
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
A2 Biotherapeutics Inc.
Palleon Pharmaceuticals, Inc.
Sensei Biotherapeutics, Inc.
Centre for Research and Technology Hellas
Apollomics Inc.
ModeX Therapeutics, An OPKO Health Company
Hoffmann-La Roche
Compugen Ltd
Columbia University
Tempus AI
Arbeitsgemeinschaft medikamentoese Tumortherapie
Vyriad, Inc.
Intensity Therapeutics, Inc.
Cyprus University of Technology
PureTech
Rutgers, The State University of New Jersey
Universidade Federal de Pernambuco
Eli Lilly and Company
Taproot Health
NextCure, Inc.
VitaMed Research LLC
Washington University School of Medicine
European Organisation for Research and Treatment of Cancer - EORTC